Compounds > tiropramide

Page last updated: 2024-12-06

tiropramide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID Source	ID
PubMed CID	42262
CHEMBL ID	2104688
CHEBI ID	135758
SCHEMBL ID	25693
MeSH ID	M0098137

Synonyms (36)

Synonym
tiropramide
maioral
cr-605
tirospan
brn 4162600
tiropramida [inn-spanish]
(+-)-alpha-(benzoylamino)-4-(2-(diethylamino)ethoxy)-n,n-dipropylbenzenepropanamide
dl-alpha-benzamido-para-(2-(diethylamino)ethoxy)-n,n-dipropylhydrocinnamamide
tiropramidum [inn-latin]
benzenepropanamide, alpha-(benzoylamino)-4-(2-(diethylamino)ethoxy)-n,n-dipropyl-, (+-)-
tiropramida [spanish]
dl-alpha-benzamido-p-(2-(diethylamino)ethoxy)-n,n-dipropylhydrocinnamamide
tiropramide [inn]
o-(diethylaminoethyl)-n-benzoyl-dl-tyrosyl-di-n-propylamide
D07087
tiropramide (inn)
55837-29-1
CHEBI:135758
tiropramida
r7s0904cn2 ,
unii-r7s0904cn2
tiropramidum
CHEMBL2104688
AKOS015909639
SCHEMBL25693
dl-.alpha.-benzamido-p-(2-(diethylamino)ethoxy)-n,n-dipropylhydrocinnamamide
tiropramide [mi]
(+/-)-.alpha.-benzamido-p-(2-(diethylamino)ethoxy)-n,n-dipropylhydrocinnamamide
tiropramide [who-dd]
n-(2-{4-[2-(diethylamino)ethoxy]phenyl}-1-(dipropylcarbamoyl)ethyl)benzenecarboximidic acid
n-[3-[4-[2-(diethylamino)ethoxy]phenyl]-1-(dipropylamino)-1-oxopropan-2-yl]benzamide
DB13091
Q7809264
DTXSID70866514
(+/-)-tiropramide
n-(3-(4-(2-(diethylamino)ethoxy)phenyl)-1-(dipropylamino)-1-oxopropan-2-yl)benzamide

Research Excerpts

Overview

Tiropramide is an antispasmodic drug that has a chiral center.

Excerpt	Reference	Relevance
"Tiropramide is an antispasmodic drug that has a chiral center. "	( Enantioseparation of tiropramide by HPLC. Choi, ES; Heo, KS; Lee, W; Park, JH; Ryoo, JJ, 2004)	2.09

Actions

Tiropramide was found to inhibit both Ca uptake and Ca release in the guinea pig urinary bladder. It did not affect cAMP and cGMP levels in the smooth muscles of the urethra, stomach and intestines.

Excerpt	Reference	Relevance
"In tiropramide, the lower boundary of CI computed from ICA or PCA results was less than 0.800 for the 3 small sample sizes (n = 22, 16, 10), but that of NCA results was less than 0.800 for only the smallest sample size (n = 10)."	( Compartmental approach to assess bioequivalence compared to the noncompartmental approach. Kang, D; Kim, BH; Kim, SE; Zheng, R, 2016)	0.95
"Tiropramide at the lower concentrations did not affect cAMP and cGMP levels in the smooth muscles of the urethra, stomach and intestines."	( [Experimental studies of urinary incontinence. Effect of tiropramide on the urinary stage and evacuation]. Ando, M; Dokita, S; Hirano, S; Kondo, S; Morita, T; Tsuchida, S, 1992)	1.25
"3. Tiropramide was found to inhibit both Ca uptake and Ca release in the guinea pig urinary bladder."	( Pharmacological properties of tiropramide, an antispasmodic drug. Hisayama, T; Iwase, M; Nagai, H; Sakuma, N; Takayanagi, I, 1989)	1.08

Pharmacokinetics

Excerpt	Reference	Relevance
" bolus the plasma levels of tiropramide are consistent with a three-compartment open pharmacokinetic model."	( Pharmacokinetics of tiropramide after single doses in man. Arigoni, R; Chisté, R; Drovanti, A; Makovec, F; Senin, P; Setnikar, I, 1986)	0.89
" Cmax values of test and reference formulations were 93."	( Pharmacokinetics and bioequivalence of tiropramide in healthy volunteers. Chung, YB; Kwon, OS; Park, YJ, 2003)	0.59
"A pharmacokinetic interaction between oral DA-8159 and amlodipine was evaluated in male Sprague-Dawley rats."	( Negligible pharmacokinetic interaction between oral DA-8159, a new erectogenic, and amlodipine in rats. Kim, EJ; Kwon, JW; Lee, JH; Lee, MG; Yoo, M, 2006)	0.33

Bioavailability

Excerpt	Reference	Relevance
" Bioavailability differences for Cmax and AUC0-->last were -2."	( Pharmacokinetics and bioequivalence of tiropramide in healthy volunteers. Chung, YB; Kwon, OS; Park, YJ, 2003)	0.59

Dosage Studied

Excerpt	Relevance	Reference
" The knowledge gained by these studies was used to predict drug degradation profiles, which help analyse any impurities in the dosage form."	( Chromatographic separation of tiropramide hydrochloride and its degradation products along with their structural characterization using liquid chromatography quadrupole time-of-flight tandem mass spectrometry and nuclear magnetic resonance. Gananadhamu, S; Golla, VM; Kushwah, BS; Naik, DD; Tidke, M, 2023)	1.2

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

Class	Description
phenylalanine derivative	An amino acid derivative resulting from reaction of alanine at the amino group or the carboxy group, or from the replacement of any hydrogen of phenylalanine by a heteroatom. The definition normally excludes peptides containing phenylalanine residues.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (36)

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	22 (61.11)	18.7374
1990's	4 (11.11)	18.2507
2000's	8 (22.22)	29.6817
2010's	1 (2.78)	24.3611
2020's	1 (2.78)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 50.05

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

Metric	This Compound (vs All)
Research Demand Index	50.05 (24.57)
Research Supply Index	3.93 (2.92)
Research Growth Index	4.65 (4.65)
Search Engine Demand Index	76.23 (26.88)
Search Engine Supply Index	2.00 (0.95)

This Compound (50.05)

All Compounds (24.57)

Study Types

Publication Type	This drug (%)	All Drugs (%)
Trials	12 (31.58%)	5.53%
Reviews	0 (0.00%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	26 (68.42%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (1)

Trial Overview

Trial			Phase	Enrollment	Study Type	Start Date	Status
Comparative and Analytical Study for Effectiveness and Safety of Tiropramide HCl and Octylonium Bromide in the Treatment of Irritable Bowel Syndrome: Mullticenter, Randomized, Double Blind, Active Controlled Study [NCT01629212]			Phase 4	0 participants	Interventional	2011-12-31	Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Substance	Relationship Strength	Studies	Trials	Classes	Roles
adenine [no description available]	2.13	1	0	6-aminopurines; purine nucleobase	Daphnia magna metabolite; Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
amlodipine Amlodipine: A long-acting dihydropyridine calcium channel blocker. It is effective in the treatment of ANGINA PECTORIS and HYPERTENSION.. amlodipine : A fully substituted dialkyl 1,4-dihydropyridine-3,5-dicarboxylate derivative, which is used for the treatment of hypertension, chronic stable angina and confirmed or suspected vasospastic angina.	2.03	1	0	dihydropyridine; ethyl ester; methyl ester; monochlorobenzenes; primary amino compound	antihypertensive agent; calcium channel blocker; vasodilator agent
flavoxate Flavoxate: A drug that has been used in various urinary syndromes and as an antispasmodic. Its therapeutic usefulness and its mechanism of action are not clear. It may have local anesthetic activity and direct relaxing effects on smooth muscle as well as some activity as a muscarinic antagonist.. flavoxate : A carboxylic ester resulting from the formal condensation of 3-methylflavone-8-carboxylic acid with 2-(1-piperidinyl)ethanol.	2.38	2	0	carboxylic ester; flavones; piperidines; tertiary amino compound	antispasmodic drug; muscarinic antagonist; parasympatholytic
indomethacin Indomethacin: A non-steroidal anti-inflammatory agent (NSAID) that inhibits CYCLOOXYGENASE, which is necessary for the formation of PROSTAGLANDINS and other AUTACOIDS. It also inhibits the motility of POLYMORPHONUCLEAR LEUKOCYTES.. indometacin : A member of the class of indole-3-acetic acids that is indole-3-acetic acid in which the indole ring is substituted at positions 1, 2 and 5 by p-chlorobenzoyl, methyl, and methoxy groups, respectively. A non-steroidal anti-inflammatory drug, it is used in the treatment of musculoskeletal and joint disorders including osteoarthritis, rheumatoid arthritis, gout, bursitis and tendinitis.	1.96	1	0	aromatic ether; indole-3-acetic acids; monochlorobenzenes; N-acylindole	analgesic; drug metabolite; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; environmental contaminant; gout suppressant; non-steroidal anti-inflammatory drug; xenobiotic metabolite; xenobiotic
oxybutynin oxybutynin: RN given refers to parent cpd. oxybutynin : A racemate comprising equimolar amounts of (R)-oxybutynin and esoxybutynin. An antispasmodic used for the treatment of overactive bladder.	2.38	2	0	acetylenic compound; carboxylic ester; racemate; tertiary alcohol; tertiary amino compound	antispasmodic drug; calcium channel blocker; local anaesthetic; muscarinic antagonist; muscle relaxant; parasympatholytic
papaverine Papaverine: An alkaloid found in opium but not closely related to the other opium alkaloids in its structure or pharmacological actions. It is a direct-acting smooth muscle relaxant used in the treatment of impotence and as a vasodilator, especially for cerebral vasodilation. The mechanism of its pharmacological actions is not clear, but it apparently can inhibit phosphodiesterases and it may have direct actions on calcium channels.. papaverine : A benzylisoquinoline alkaloid that is isoquinoline substituted by methoxy groups at positions 6 and 7 and a 3,4-dimethoxybenzyl group at position 1. It has been isolated from Papaver somniferum.	1.98	1	0	benzylisoquinoline alkaloid; dimethoxybenzene; isoquinolines	antispasmodic drug; vasodilator agent
trimebutine Trimebutine: Proposed spasmolytic with possible local anesthetic action used in gastrointestinal disorders.	4.32	2	2	trihydroxybenzoic acid
carbachol Carbachol: A slowly hydrolyzed CHOLINERGIC AGONIST that acts at both MUSCARINIC RECEPTORS and NICOTINIC RECEPTORS.	1.98	1	0	ammonium salt; carbamate ester	cardiotonic drug; miotic; muscarinic agonist; nicotinic acetylcholine receptor agonist; non-narcotic analgesic
tyrosine Tyrosine: A non-essential amino acid. In animals it is synthesized from PHENYLALANINE. It is also the precursor of EPINEPHRINE; THYROID HORMONES; and melanin.. tyrosine : An alpha-amino acid that is phenylalanine bearing a hydroxy substituent at position 4 on the phenyl ring.	8.39	35	11	amino acid zwitterion; erythrose 4-phosphate/phosphoenolpyruvate family amino acid; L-alpha-amino acid; proteinogenic amino acid; tyrosine	EC 1.3.1.43 (arogenate dehydrogenase) inhibitor; fundamental metabolite; micronutrient; nutraceutical
terodiline [no description available]	1.98	1	0	diarylmethane
colforsin Colforsin: Potent activator of the adenylate cyclase system and the biosynthesis of cyclic AMP. From the plant COLEUS FORSKOHLII. Has antihypertensive, positive inotropic, platelet aggregation inhibitory, and smooth muscle relaxant activities; also lowers intraocular pressure and promotes release of hormones from the pituitary gland.	1.98	1	0	acetate ester; cyclic ketone; labdane diterpenoid; organic heterotricyclic compound; tertiary alpha-hydroxy ketone; triol	adenylate cyclase agonist; anti-HIV agent; antihypertensive agent; plant metabolite; platelet aggregation inhibitor; protein kinase A agonist
fura-2 Fura-2: A fluorescent calcium chelating agent which is used to study intracellular calcium in tissues.	1.98	1	0
finasteride Finasteride: An orally active 3-OXO-5-ALPHA-STEROID 4-DEHYDROGENASE inhibitor. It is used as a surgical alternative for treatment of benign PROSTATIC HYPERPLASIA.. finasteride : An aza-steroid that is a synthetic drug for the treatment of benign prostatic hyperplasia.	2.13	1	0	3-oxo steroid; aza-steroid; delta-lactam	androgen antagonist; antihyperplasia drug; EC 1.3.1.22 [3-oxo-5alpha-steroid 4-dehydrogenase (NADP(+))] inhibitor
adefovir adefovir: inhibitor of African swine fever virus. adefovir(1-) : A organophosphonate oxoanion obtained by removal of a proton from the phosphonate group of adefovir, a nucleoside reverse transcriptase inhibitor. It is the major microspecies at pH 7.3 (according to Marvin v 6.2.0.).. adefovir : A member of the class of phosphonic acids that is methylphosphonic acid in which one of the methyl hydrogens has been replaced by a 2-(6-amino-9H-purin-9-yl)ethoxy group. An inhibitor of HIV-1 reverse transcriptase, the bis(t-butoxycarbonyloxymethyl) ester (dipivoxil ester) prodrug is used to treat chronic hepatitis B viral infection.	2.13	1	0	6-aminopurines; ether; phosphonic acids	antiviral drug; DNA synthesis inhibitor; drug metabolite; HIV-1 reverse transcriptase inhibitor; nephrotoxic agent
octylonium octylonium: RN given refers to bromide; structure	4.96	3	3	benzamides
organophosphonates hydrogenphosphite : A divalent inorganic anion resulting from the removal of a proton from two of the hydroxy groups of phosphorous acid.	2.13	1	0	divalent inorganic anion; phosphite ion
troleandomycin Troleandomycin: A macrolide antibiotic that is similar to ERYTHROMYCIN.. troleandomycin : A semi-synthetic macrolide antibiotic obtained by acetylation of the three free hydroxy groups of oleandomycin. Troleandomycin is only found in individuals that have taken the drug.	2.03	1	0	acetate ester; epoxide; macrolide antibiotic; monosaccharide derivative; polyketide; semisynthetic derivative	EC 1.14.13.97 (taurochenodeoxycholate 6alpha-hydroxylase) inhibitor; xenobiotic
hymecromone Hymecromone: A coumarin derivative possessing properties as a spasmolytic, choleretic and light-protective agent. It is also used in ANALYTICAL CHEMISTRY TECHNIQUES for the determination of NITRIC ACID.	3.35	1	1	hydroxycoumarin	antineoplastic agent; hyaluronic acid synthesis inhibitor
morphine Meconium: The thick green-to-black mucilaginous material found in the intestines of a full-term fetus. It consists of secretions of the INTESTINAL GLANDS; BILE PIGMENTS; FATTY ACIDS; AMNIOTIC FLUID; and intrauterine debris. It constitutes the first stools passed by a newborn.	1.97	1	0	morphinane alkaloid; organic heteropentacyclic compound; tertiary amino compound	anaesthetic; drug allergen; environmental contaminant; geroprotector; mu-opioid receptor agonist; opioid analgesic; plant metabolite; vasodilator agent; xenobiotic
phosphorus Phosphorus: A non-metal element that has the atomic symbol P, atomic number 15, and atomic weight 31. It is an essential element that takes part in a broad variety of biochemical reactions.	8.8	2	1	monoatomic phosphorus; nonmetal atom; pnictogen	macronutrient
sincalide Sincalide: An octapeptide hormone present in the intestine and brain. When secreted from the gastric mucosa, it stimulates the release of bile from the gallbladder and digestive enzymes from the pancreas.	1.97	1	0	oligopeptide
cyclic gmp Cyclic GMP: Guanosine cyclic 3',5'-(hydrogen phosphate). A guanine nucleotide containing one phosphate group which is esterified to the sugar moiety in both the 3'- and 5'-positions. It is a cellular regulatory agent and has been described as a second messenger. Its levels increase in response to a variety of hormones, including acetylcholine, insulin, and oxytocin and it has been found to activate specific protein kinases. (From Merck Index, 11th ed). 3',5'-cyclic GMP : A 3',5'-cyclic purine nucleotide in which the purine nucleobase is specified as guanidine.	1.97	1	0	3',5'-cyclic purine nucleotide; guanyl ribonucleotide	Escherichia coli metabolite; human metabolite; mouse metabolite; plant metabolite; Saccharomyces cerevisiae metabolite
da 8159 udenafil: a pyrazolo-pyrimidinone similar to sildenafil; phosphodiesterase type 5 inhibitor;	2.03	1	0	sulfonamide
da-8164 DA-8164: metabolite of DA-8159; structure in first source	2.03	1	0	sulfonamide

Condition	Relationship Strength	Studies	Trials
Muscle Contraction A process leading to shortening and/or development of tension in muscle tissue. Muscle contraction occurs by a sliding filament mechanism whereby actin filaments slide inward among the myosin filaments.	3.48	8	0
Muscle Relaxation That phase of a muscle twitch during which a muscle returns to a resting position.	6.96	1	0
Colonic Diseases, Functional Chronic or recurrent colonic disorders without an identifiable structural or biochemical explanation. The widely recognized IRRITABLE BOWEL SYNDROME falls into this category.	5.44	4	4
Acute Post-operative Pain [description not available]	3.35	1	1
Complication, Postoperative [description not available]	3.35	1	1
Pain, Postoperative Pain during the period after surgery.	3.35	1	1
Postoperative Complications Pathologic processes that affect patients after a surgical procedure. They may or may not be related to the disease for which the surgery was done, and they may or may not be direct results of the surgery.	3.35	1	1
Indigestion [description not available]	1.96	1	0
Symptom Cluster [description not available]	1.96	1	0
Gallbladder Dyskinesia [description not available]	3.75	2	1
Biliary Dyskinesia A motility disorder characterized by biliary COLIC, absence of GALLSTONES, and an abnormal GALLBLADDER ejection fraction. It is caused by gallbladder dyskinesia and/or SPHINCTER OF ODDI DYSFUNCTION.	3.75	2	1
Dyspepsia Impaired digestion, especially after eating.	1.96	1	0
Syndrome A characteristic symptom complex.	6.96	1	0
Bladder Disorder, Neurogenic [description not available]	1.98	1	0
Urinary Bladder, Neurogenic Dysfunction of the URINARY BLADDER due to disease of the central or peripheral nervous system pathways involved in the control of URINATION. This is often associated with SPINAL CORD DISEASES, but may also be caused by BRAIN DISEASES or PERIPHERAL NERVE DISEASES.	1.98	1	0
Urinary Incontinence Involuntary loss of URINE, such as leaking of urine. It is a symptom of various underlying pathological processes. Major types of incontinence include URINARY URGE INCONTINENCE and URINARY STRESS INCONTINENCE.	6.98	1	0
Decerebrate Posturing [description not available]	1.98	1	0
Diarrhea An increased liquidity or decreased consistency of FECES, such as running stool. Fecal consistency is related to the ratio of water-holding capacity of insoluble solids to total water, rather than the amount of water present. Diarrhea is not hyperdefecation or increased fecal weight.	3.76	2	1
Colon Diverticula [description not available]	1.97	1	0
Diverticulum, Colon A pouch or sac opening from the COLON.	1.97	1	0
Intestinal Polyps Discrete abnormal tissue masses that protrude into the lumen of the INTESTINE. A polyp is attached to the intestinal wall either by a stalk, pedunculus, or by a broad base.	1.97	1	0
Pregnancy The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH.	1.97	1	0
Colonic Inertia Symptom characterized by the passage of stool once a week or less.	3.35	1	1
Constipation Infrequent or difficult evacuation of FECES. These symptoms are associated with a variety of causes, including low DIETARY FIBER intake, emotional or nervous disturbances, systemic and structural disorders, drug-induced aggravation, and infections.	3.35	1	1

chemdatabank.com